Editas Medicine (LTS:0IFK) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0IFK Editas Medicine Inc LTS:0IFK
52 GF Score
Price $2.98
GF Value $1.79
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Editas Medicine Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Editas Medicine Quality Rank Related Terms

LTS:0IFK
52GF Score
Editas Medicine Inc LTS:0IFK
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Editas Medicine (LTS:0IFK) Overvalued in 2026?

Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued. The current stock price of $2.98 is trading 66.5% above its estimated GF Value™ of $1.79. GuruFocus considers Editas Medicine to be Significantly Overvalued.

Key valuation signals for LTS:0IFK:

  • Quality Rank:
  • GF Value™: $1.79 vs. price of $2.98 (66.5% above fair value)
  • GF Score™: 52/100 with 8 warning signs

No single metric tells the full story. See the LTS:0IFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Editas Medicine Business Description

Other Exchanges EDIT:USA8EM:Germany
Address 11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
52GF Score

Get the complete analysis for LTS:0IFK

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.98
Price
$1.79
GF Value